ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

• Main Authors: Tatiana Galicia-Carmona (Author), Eder Arango-Bravo (Author), Juan a Serrano-Olvera (Author), Celia Flores-de La Torre (Author), Ivan Cruz-Esquivel (Author), Ricardo Villalobos-Valencia (Author), Andrés Morán-Mendoza (Author), Denisse Castro-Eguiluz (Author), Lucely Cetina-Pérez (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live attenuated Listeria monocytogenes-listeriolysin O (L...